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ABSTRACT 
 
Natural products have long been a template by which science has produced medicines 
which have saved millions of lives. Bacterial sources have yielded many peptide based 
drugs which continue to show great value against targets such as Gram-positive and 
Gram-negative infections. In this work, we will present two natural products yielded 
from Burkholderia contaminans and Streptococcus mutans bacteria which have shown 
great promise against multiple cancer cell lines and Gram-positive infections, 
respectively. B. contaminans produces occidiofungin, a non-ribosomally synthesized 
cyclic peptide with antifungal properties. Testing against several cancer lines, including 
ovarian cancer and B-cell lymphoma showed that occidiofungin had efficacy against the 
cancer lines at a concentration 75 times lower than cytotoxic dosing attempts in mice. S. 
mutans produces mutacin 1140, a lantibiotic product which is ribosomally synthesized 
and undergoes posttranslational modifications. We have found that in vitro dosing of 
mutacin 1140 in combination with an aminoglycoside, kanamycin against 
Staphylococcus aureus results in a synergistic inhibition effect. Both of these 
compounds possess great potential as therapeutics. 
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CHAPTER I  
 
INTRODUCTION: CHALLENGES FACING ANTIBIOTIC TREATMENTS AND 
ANTIFUNGALS  
 
Each year, at least 2 million people become infected with bacteria resistant to antibiotics, 
causing at least 23,000 deaths as a direct result of their infections [1]. Drug resistance 
has become a major issue with most pathogens, but especially with Staphylococcus 
aureus. There are over 30 types of Staph bacteria, with Staphylococcus aureus causing 
the majority of staph infections. Methicillin resistant Staphylococcus aureus (MRSA) 
infections cost a single 200-bed hospital an average of $1,779,283 annually [2]. MRSA 
infections are particularly difficult to treat as several front line drugs are ineffective 
against it [3]. MRSA also greatly affects those who are already immune compromised 
[4]. Of particular concern are hospital acquired infections (HAI), as most common HAIs 
are caused by drug-resistant bacteria, including the previously mentioned MRSA; 
vancomycin-resistant Enterococcus faecalis, (VRE); and Clostridium difficile, or C. diff. 
According to the Centers for Disease Control and Prevention (CDC), HAIs are estimated 
to occur in approximately 5% of all acute-care hospitalizations [1]. The CDC also 
estimates that the total medical cost to the U.S. healthcare system from hospital acquired 
infections is between $35.7 billion to $45 billion annually [1]. A recent CDC hospital 
infection survey with 2,039 hospitals reporting [5] revealed eight pathogen groups 
accounted for about 80% of reported pathogens. Gram-positive cocci (GPC) cause the 
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majority of hospital acquired infections with Staphylococcus aureus (16%, with more 
than 50% being methicillin-resistant [MRSA]) and Enterococcus species (14%, with 
vancomycin-resistant enterococci [VRE] accounting for approximately 3.5% of all 
infections) [5]. Nearly 20% of pathogens reported from all HAIs were the following 
multidrug-resistant phenotypes: MRSA (8.5%); vancomycin-resistant Enterococcus 
(3%); extended-spectrum cephalosporin-resistant K. pneumoniae and K. oxytoca (2%), 
E. coli (2%), and Enterobacter spp. (2%); and carbapenem-resistant P. aeruginosa (2%), 
K. pneumoniael oxytoca (<1%) [5].  
 
A brief summary of the current antibiotic classes and their general targets in bacteria is 
presented here. Cell wall biosynthesis is inhibited by ß-lactam containing compounds, 
such as penicillins and cephalosporins, which inhibit peptidoglycan polymerization by 
binding penicillin β-lactam ring of penicillin to the enzyme DD-transpeptidase. DD-
transpeptidase cannot catalyze formation of these cross-linkages, which causes an 
imbalance between degradation and cell wall production leading to lysis from an 
osmotic pressure increase. Polymyxins disrupt the plasma membrane, binding to 
lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria and causing 
cell death. The plasma membrane sterols of fungi are attacked by polyenes 
(amphotericin) and imidazoles. Quinolones bind to a bacterial complex of DNA and 
DNA gyrase, blocking DNA replication. Nitroimidazoles select for anaerobic bacteria 
due to their ability to reduce metronidazole to its active form. This reduced 
metronidazole can then covalently binds to DNA, disrupt its structure, inhibiting 
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bacterial nucleic acid synthesis and resulting in cell death. Rifampin inhibits DNA-
dependent RNA polymerase activity. It accomplishes this by forming a stable complex 
with the enzyme, then suppressing the initiation of RNA synthesis. Aminoglycosides, 
chloramphenicol, tetracycline, clindamycin, erythromycin, interfere with ribosome 
function causing the creation of junk peptide fragments and cell death. Lastly, 
sulfonamides and trimethoprim block the synthesis of the folate required for DNA 
replication. Sulfonamides stop folic acid synthesis by preventing para-aminobenzoic 
acid (PABA) addition into the folic acid molecule. 
 
While reasons for drug resistance development vary, one reason stems from over 
prescription and patient dosage regimen incompletion, giving the bacteria constant 
association with the compound and developing resistance [6]. Other reasons include 
biological resistance mechanisms from the bacteria themselves, including the use of 
multidrug efflux pumps, that is, proteins that cells use to detoxify and export antibiotic 
compounds from the cell. Pumps seem to play a key role in the emergence of these 
multidrug resistant (MDR) bacteria [7]. Some resistant bacteria defeat antibiotics by 
changing critical target sites to avoid recognition by the drug. This has been clinically 
observed with Enterococci altering its cell wall precursor components to decrease 
successful binding of vancomycin [8].  Of note as well is the lean pipeline of antibiotic 
candidates [9] against the so called “ESKAPE” pathogens: Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas 
aeruginosa, and Enterobacter species [10] .  
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There is a persistent need not only for novel drug candidates to treat these infections, but 
also for effective dosing strategies with currently available drugs [9]. Effective 
combinatorial therapy will allow for a reduction in dose necessary to reach the 
equivalent (or higher) level of efficacy, which in turn reduces toxicological concerns for 
drugs currently in the clinic which may still possess efficacy but may cause harmful side 
effects. An example of such an antibiotic with a high use clinically are the 
fluoroquinolone class which feature a significantly increased risk of kidney failure in 
treated patients [11]. The best known examples of fluoroquinolones are Cipro 
(ciprofloxacin), Levaquin (levofloxacin) and Avelox (moxifloxacin). Combinatorial 
therapy also provides multiple points of attack for bacteria inhibition, reducing the risk 
of resistance development in response. In the case of peptide based therapeutics, 
combinatorial therapy may be especially useful due to limited sourcing and expensive 
overhead to produce these bacteria synthesized compounds. Current combinatorial 
therapy strategies include pairing of 1 or more antibiotics into a treatment regimen, 
which, for the most part is used as a strategy of resistance suppression. Presenting the 
bacteria with different targets slows the adaptation and resistance mechanism due to 
multiple mutations being required. Examples of current combinatorial strategies include 
combining doxycycline and rifampin (for treatment of endocarditis), as well as β-lactam 
drugs with β-lactamase inhibitors (Clavunate and Amoxicillin) to combat maladies such 
as sinusitis, pneumonia (usual adult dose calls for 500 mg orally every 8 hours or 875 
mg orally every 12 hours) ear infections, bronchitis, urinary tract infections, and 
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infections of the skin. Combinatorial therapies continue to be a powerful clinical 
weapon; however, in and of itself, is not enough to completely stem the tide of 
resistance. New candidate drugs and approaches are needed. 
 
Peptide-Based Therapeutics  
Antimicrobial peptides have been studied and analyzed for over 30 years [12, 13]. 
Peptides are recognized for being highly selective against target bacteria, effective and 
relatively safe and well tolerated by patients. Side effects are also milder in comparison 
with other chemi-therapeutics. Currently, there are more than 60 US Food and Drug 
Administration (FDA)-approved peptide therapeutics on the market; this is expected to 
grow significantly, with  more than 500 therapeutic peptides in preclinical development 
and approximately 140 peptide drugs currently in clinical trials and [14] [15]. Because of 
peptide’s attractive chemical profile and useful properties, peptides represent a 
promising starting point for novel drug design [15]. These antibiotics normally are 
classified as either non-ribosomally synthesized (NRS) or ribosomally synthesized 
peptides. Examples of NRS peptides include polymyxins, gramicidins, glycopeptides, 
and bacitracins. Many NRS peptides are produced by bacteria from the genus 
Streptomyces (actinomycin, bacitracin, daptomycin, vancomycin, and teixobactin) and 
are modified; the ribosomally synthesized peptides are produced by nearly all species. 
These peptides are normally small (<10 KDa) and of variable length, structure, and 
sequence [16]. It is this widespread variety and lack of rigid homology which lead to the 
belief that these peptides were developed over time by multiple species as  defense 
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mechanisms [17]. The significance of naturally produced cationic peptide antibiotics is 
reflected in their evolutionary origin as inhibitory substances that microbes use against 
each other [18]. Ribosomally synthesized antibiotic peptides have been isolated from 
invertebrates and vertebrates, plants, fungi, and bacteria [19]. Most of these peptides 
may act by selectively disrupting the plasma membrane leading to lysis of the cell [20]. 
Several peptides have entered clinical trials for treatments such as impetigo (xoma), and 
diabetic foot ulcers (a thrombin derived peptide used to promote wound healing, 
chrysalin) [16]. Some of the newest antibiotics to enter the clinic are peptides, such as 
echinocandins and daptomycin. Echinocandins are a relatively new class of drug which 
at the time of discovery, represented the first novel class of antifungals in more than 15 
years [21]. Their mechanism of action (MOA) is to stop synthesis of β-D-glucan in 
fungal cell walls. Positive characteristics of echinocandins include rapid fungicidal 
activity against Candida spp. and low toxicity.  
 
Daptomycin is a naturally occurring lipopeptide antibiotic found in the soil saprotroph 
(extracellular digestion involved in the processing of decayed organic 
matter)  Streptomyces roseosporus, isolated by scientists at Eli Lilly from a soil sample 
from Mount Ararat, Turkey. Daptomycin underwent clinical trials in the late 1980s and 
early 1990s [22], and is active against multiple categories of  Gram-positive bacteria, 
including MRSA and enterococci [23]. Further studies elucidated that the mechanism of 
action for daptomycin was that it facilitated formation of membrane distortions. These 
distortions or membrane patches are able to attract the cell division protein DivIVA 
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which has been linked with the formation of  defects in the membrane  and cell 
morphology changes; it is thought to be  essential [24]. This suggests an alteration in the 
enzyme activity involved in the process of cell wall synthesis that could account for 
previously described effects of daptomycin on cell wall morphology [24].Recent success 
points to the need for new drugs coming from peptide synthesizing sources [15]. 
However, there is still more that needs to be done to study peptide based compounds for 
clinical use.  
 
The Smith lab has a research focus on the understanding of the structure and function of 
natural therapeutic products [25]. This work will provide a foundation for research 
aimed at understanding their efficacy for use in the treatment and prevention of human 
and animal diseases and as potential biological control agents in agriculture. The 
discovery of novel antimicrobials and the study of antimicrobial function have 
significant relevance towards the development of therapeutics aimed at treating life-
threatening diseases [25]. Moreover, much of what we have learned about protein 
synthesis, DNA replication, enzyme function, and membrane physiology comes from the 
study of the effect of antimicrobial compounds on the physiology of the target bacteria. 
The structural and functional characterization of new antimicrobial agents will help 
provide new insights into cellular processes and membrane physiology, as well as 
provide a means to rationally design new analogs that target microbial function [25]. The 
discovery of new enzymes involved in natural product synthesis also offers invaluable 
information for understanding the complexity of microorganisms and provide tools for 
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synthetic chemistry applications [25]. Two of the natural product peptides we are 
focused on are mutacin 1140, a Gram-positive inhibitor which binds lipid II, and 
occidiofungin, an antifungal compound. 
 
Mutacin 1140  
Streptococcus mutans JH1140 is a Gram-positive coccus-shaped bacteria naturally 
occurring  in the oral cavity of some individuals; it is a known contributor to tooth decay 
[26]. It was first discovered by J Kilian Clarke in 1924 [27, 28]. S. mutans helps cause 
tooth decay by creating an acidic environment in the mouth through breaking down 
sucrose to lactic acid utilizing the enzyme glucansucrase. S. mutans produces dextran by 
using the enzyme dextransucrase and sucrose as a target substrate.  
 
S. mutans produces a 22 amino acid post-translationally modified peptide product, 
named mutacin 1140 (Figure 1). Mutacin 1140 was first discovered by Hillman in 1998 
after performing homology analysis of the band resulting from a stab of a spontaneous 
mutant (JH1140) of JH1000 which produced threefold-elevated amounts of activity [26]. 
Mutacin 1140 is a bacteriocin (Class 1) showing effective inhibition against Gram-
positive bacteria [29]. Mutacin 1140 is classified as a type A lantibiotic, forming unique 
lanthionine rings in the 1140 structure [29]. Lantibiotics are peptide antibiotics that 
feature amino acids such as lanthionine or methyllanthionine, as well as unsaturated 
amino acids dehydroalanine and 2-aminoisobutyric acid. Its antibacterial properties are 
activated by cleavage of an N-terminal leader [30, 31]. Multiple Gram-positive bacteria 
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like Streptomyces and Streptococcus produce lantibiotics in order to eliminate other 
Gram-positive bacteria competitors [32]. Nisin is of this same class, (perhaps the best 
known example) and has been used for several decades as a food preservative [33] 
(Figure 1). The ring structures A and B are conserved between mutacin 1140 and nisin, 
and are thought to house the region which binds lipid II. Lanthipeptides, (the newer term 
to replace lantibiotics) have applications as probiotics, therapeutic agents for the 
treatment of human diseases, and the biosynthetic enzymes have protein chemistry 
applications. No protein receptor is required for the bactericidal activity of this class of 
antibiotics, and therefore, resistance is not easily developed via genetic adaptation due to 
the conservation of the lipid II target.  At this point, genetically stable resistant strains to 
mutacin 1140 have not been found, suggesting that the chemistry and structure of 
mutacin 1140 may prove valuable as a template for further development of synthetic 
antibiotics [34].  
 
Mutacin 1140 features amino acids such as methyllanthionine (Abu-S-Ala), lanthionine 
(Ala-S-Ala), didehydroalanine (DHA) and didehydrobuterine (DHB)[35]. Mutacin 1140 
is biosynthesized in a series of dehydration steps to its serines (yielding DHA) and 
threonines (yielding DHB)[36]. It is the formation of a structural ring between the 
cysteine and either DHA or DHB which forms a lanthionine ring [37]. For these post- 
translational modifications to occur, several actors forming the biosynthetic gene cluster 
must be present, including lanA (lantibiotic peptide, Figure 2A), lanB (dehydratase actor, 
Figure 2B), lanC (which helps facilitate thioether connections and causes cyclization 
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Figure 2C), decarboxylation by lanD (Figure 2D) and lanT, a transporter which allows 
the movement of the peptide [37](Figure 2E). LanP, a protease, performs the important 
step of cleaving the leader sequence, activating the peptide for lipid II sequestration [38] 
(Figure 2E).  
 
Mutacin 1140’s mechanism of action is to sequester and abduct bacterial lipid II, 
preventing and disrupting cell wall biosynthesis. Lipid II is a peptidoglycan precursor 
which anchors itself in the bacterial membrane [39] (Figure 3). Its main purpose is to 
facilitate a transportation network by which peptidoglycan “building blocks” are moved 
from the cytoplasm to the membrane surface [39]. Lipid II is an essential component for 
bacterial cell wall integrity. Compounds which attack lipid II can be especially useful 
due to both the essentiality of lipid II and the low chance of lipid II target resistance 
development. Lantibiotics have also been shown to disrupt plasma membranes [40]. 
Previous studies using nisin as a guide elucidated that, unlike nisin, mutacin 1140 does 
not form a lipid II facilitated pore complex [29]. Further experimentation using 
fluorescence techniques reveals that mutacin 1140 and nisin competitively bind lipid II.  
Other current lantibiotics in development include one from Novacta Biosystems Ltd, a 
type-B lantibiotic-based compound that has antibacterial activity PCT/GB2008/002463). 
The compound is proposed for use in therapy or prophylaxis for infections caused by 
Clostridium difficile and for treatment of pseudomembranous colitis [18].  
Limited work has been done in combining lantibiotics with other therapeutics to assess 
synergistic or additive affects. Recent literature [41] has appeared which shows 
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synergistic effects against S. aureus when nisin is combined with cinnamaldehyde. 
Cinnamaldehyde is a well-studied essential oil isolated from cinnamon bark, which 
previously was  reported to exhibit a broad spectrum of antimicrobial activity across a 
wide range of microorganisms [42]. Another study released this year (2017) shows data 
supporting synergistic behavior between nisin and citric acid against S. 
aureus and Listeria monocytogenes with fractional inhibitory concentration (FIC) 
ranging from 0.25 to .375 and 0.19 to 0.375 FIC index, respectively [43]. While these 
studies do show promise combining lantibiotics and compounds with antimicrobial 
activity, no one has reported studies showing lantibiotics in combination with FDA 
approved front line or second line antibiotics used clinically. Dosing bacteria with 
lantibiotics in combination with a secondary antibiotic partner may lead to an improved 
combinatorial strategy and synergy. I will address this idea further in Chapter III.  
 
Lantibiotics are limited in the sense that they only work against a Gram-positive 
bacteria. Their ineffectiveness against Gram-negative bacteria occurs due to their large 
size keeping them from getting through the outer membrane.  
An interesting innovation would be conferring lantibiotic activity against Gram-negative 
bacteria, either by devising a delivery system to bypass the Gram-negative outer cell 
membrane or by modifying the outer cell membrane itself before dosing to allow 
passage of the mutacin 1140 inside. Recent work by Vukomanović et al. shows some 
success in this venture; they bound nisin molecules to the surface of gold nano-features 
and used it effectively against Gram-negative bacteria (Escherichia coli and 
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Pseudomonas aeruginosa). They were able to show that this type of structure enables 
interactions capable of disrupting the outer cell membrane of Gram-negative bacteria 
[44].  
 
Another research group from Shanghai Jiao Tong University School of Medicine 
recently demonstrated successful reduction (by three orders of magnitude) of drug-
resistant Escherichia coli GN102 in a mouse peritoneal cavity using silver core-
embedded mesoporous silica nanovehicles in combination with the broad spectrum 
antibiotic Levofloxacin [45]. The novelty of their nanoparticle delivery system might be 
adapted to deliver lantibiotics into previously untreatable Gram-negative strains, further 
opening up the possibilities of lantibiotics easing the pressure on the antibiotic pipeline.  
 
Occidiofungin  
In parallel to bacterial infections, fungal infections pose a unique threat to treatment as 
there is a growing demand for new antifungals given the increasing prevalence of 
pathogens resistant to current antifungal agents. Fungal infections affect millions of 
people each year across the world, but especially those who are organ-transplant patients 
[46]. The use of medically related antifungal drugs in agriculture has resulted in 
environmental reservoirs for some drug-resistant pathogens [47]. Fungal infections also 
pose a high chance of relapse which adds another challenge to prognosis [48]. Over the 
past decade, the development of less toxic drugs, which can be applied safely in a range 
of patients with various conditions, has contributed to the expansion of antifungal use for 
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prophylaxis, and empirical and directed therapy, which has in turn led to increased drug 
resistance [49]. Current treatments for fungal infections include one of three general 
approaches: by disrupting cell wall biosynthesis (echinocandins), inhibiting ergosterol 
production (azoles), or binding of ergosterol (polyenes) [50-52]. The emergence of drug 
resistance to any one drug class severely limits therapy because so few treatment options 
are available. Multidrug resistance can eliminate treatment options entirely, which has a 
devastating effect on patient outcome. The only orally available class, the azoles, 
interacts with several groups of drugs frequently taken by patients in need of antifungal 
treatment. This can present a situation where therapeutic interference can mitigate the 
performance of the antifungal. 
 
With the increased presence of resistance against first and second line drugs, fluconazole 
and echinocandins (anidulafungin, caspofungin, and micafungin); new antifungal 
candidates are desperately needed to meet the rising challenge of fungal infections. 
Recent developments now show that there are Candida species which are resistant to all 
known clinically utilized antifungals [53]. According to the CDC, candidemia is the 
most common blood infection in the United States [54]. Even in cases where resistance 
is not present, current antifungal treatments lead to abnormal liver function test and have 
limitations with respect to their spectra of activity and toxicities. 
Occidiofungin is a 1200 Da glycolipopeptide compound (Figure 4) purified from the soil 
bacteria B. contaminans MS14 liquid culture [55]. The MS14 strain of B. contaminans 
was isolated from soil and was discovered by its ability to inhibit brown patch lawn 
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disease [56, 57]. Burkholderia contaminans is a Gram-negative, non-sporolating, rod‐
shaped, motile, aerobic bacteria which has received attention due to their infections 
being difficult to treat (normally requiring combinations of antibiotics) due to their 
resistance to antibiotics. Members of the bacteria Burkholderia exist naturally in 
environments such as water, soil, and the plant-root interface of crop plants[58]. Some 
Burkholderia strains show high efficacy in killing fungal diseases in crops and form a 
potent tool for plant disease management [59]. Unfortunately, the use of Burkholderia 
strains is not currently allowed due to the difficulty differentiating these useful strains 
from the pathogenic strains associated with the human disease cystic fibrosis [55, 60]. 
Recent work from our lab has taken steps towards addressing this issue in classifying 
pathogenic strains, by performing comparative genome‐wide analysis and sequencing on 
B. contaminans MS14. The comparison study revealed that the Burkholderia species 
genome show considerable diversity, and was different from the compared pathogenic 
strains in several key ways, namely in the absence of virulence‐associated gene loci and 
the presence of multiple antimicrobial activity‐related genes [61] . The gene cluster 
which was predicted to be responsible for the production of occidiofungin, the ocf 
cluster, was characterized and of the 16 open reading frames (ORFs) that are present in 
the cluster, five (ORF5, 6, 7, 9 and 11) were predicted to be NRPS or NRPS-PKS. ORFs 
4, 12, 13, 14 and 15 are involved in the modification of occidiofungin [62]. AmbR1 and 
AmbR2 regulate the production of occidiofungin[63]. Occidiofungin has potent 
fungicidal activity against multiple fungi including Fusarium spp., Cryptococcus 
neoformans, as well as Candida albicans. The mechanism of cell death against yeast has 
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been shown to be apoptotic [64]. MIC values for occidiofungin versus industry used 
drugs such as echinocandins and amphotericin B are comparable (submicromolar to 
micromolar) (Table 1). Previous mouse studies [56] showed that high doses did not 
result in mortality. Recent work from our lab [62] points to actin being the target of 
occidiofungin by several methods, including confocal microscopy and pull down assays 
(Figure 5). F- or G-actin incubated with the wild type occidiofungin and DMSO was 
used as a control for potential non-specific interaction of actin with the agarose beads. 
As shown in Figure 5, the biotinylation of alkyne-OF was required for the binding of F- 
or G- actin to the streptavidin beads (Lane 5 and 8). Actin was not detected in the control 
lanes (lanes 6, 7, 9 and 10). The eluant from the biotinylated alkyne-OF had a single 
band at approximately 42 kDa which is the expected size for actin. Therefore, the 
affinity purification assays done with F- or G-actin confirmed that occidiofungin binds 
to actin. Similar studies in Schizosaccharomyces pombe demonstrated localization of 
occidiofungin near the poles of the cells and in areas which are well-documented regions 
for actin patches [65] (Figure 6). Actin is a group of proteins that form filamentous 
structures (microfilaments). They are present in most eukaryotic cells.  Actin plays a key 
role during metastasis of cancer cells in transit and growth at new sites, as well as cell 
motility. For this reason, it is a high value target for cancer therapeutics and informs our 
interest in investigating whether occidiofungin might possess cancer treatment properties 
independent of its known antifungal applications.  
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CHAPTER II 
OCCIDIOFUNGIN AS A CANCER THERAPEUTIC* 
Overview 
Occidiofungin, a glyco-lipopeptide obtained from the liquid culture of Burkholderia 
contaminans MS14, has been identified as a novel fungicide. The natural product was 
shown to have a minimal amount of toxicity in a previous mouse toxicity study following 
intraperitoneal and subcutaneous administration. In this study, the toxicity of 
occidiofungin was evaluated following a 5 mg/kg intravenous tail vein injection. In 
addition, the toxicity of occidiofungin was evaluated against human fibroblast and cancer 
cell lines. Weight loss was the most significant observation following intravenous 
administration of occidiofungin. Histology, hematology, and blood serum chemistry did 
not reveal any significant signs of toxicity. The activity observed in the in vitro 
cytotoxicity assay against the cancer cell lines was all below 75 nM of occidiofungin. To 
date, the potency of occidiofungin against these cancer cell lines is greater than any 
activity observed against fungi. The findings in this study support the need to further 
evaluate occidiofungin's chemotherapeutic potential. 
_____________________________
*Reprinted with permission from “Toxicological Evaluation of Occidiofungin against Mice and Human
Cancer Cell Lines” by Steven Lai Hing, Akshaya Ravichandran, Jerome Escano, Leif Smith Pharmacology 
& Pharmacy, Vol.5 No.11, 1085-1093 Copyright 2014 by Steven Lai Hing  
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Introduction 
Occidiofungin is a compound purified from liquid culture of Burkholderia contaminans 
MS14 [57, 64, 66-71]. The compound is a non-ribosomally synthesized cyclic peptide, 
composed of eight amino acids, having a base mass of 1200 Da (Figure 2). An eighteen 
carbon fatty amino acid with a xylose sugar attached was identified in the compound, 
along with non proteinogenic amino acids 2, 4-diaminobutyric acid (DABA), and beta 
hydroxyl tyrosine and asparagine. Biological activity assays demonstrated its potent 
antifungal properties against a broad spectrum of plant and animal fungal pathogens [57, 
64, 66, 71]. 
The strong inhibitory effect of occidiofungin on Pythium spp., which does not express 
ergosterol in the cell membrane and chitin in the cell wall, suggests that inhibition of 
ergosterol or chitin biosynthesis is not a major component of occidiofungin activity. The 
inhibitory activity of occidiofungin on Fusarium spp. and Cryptococcus neoformans, 
which are resistant to echinocandins, suggests a new antifungal mechanism may be 
involved [57, 69]. Pharmacodynamic experiments revealed that occidiofungin's fungicidal 
activity against Candida albicans is more rapid than the fungicidal activity reported for 
the echinocandin antifungal caspofungin [72, 73]. Potent fungicidal activity was observed 
against Candida albicans following a short term exposure to occidiofungin for only one 
hour, suggesting that occidiofungin has a strong interaction with a cellular target [66]. 
Furthermore, the mechanism of cell death in yeast has been determined to be apoptotic 
[64]. These results indicate that occidiofungin is distinctive from the four existing classes 
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of clinically used antifungal drugs and that occidiofungin’s potential as a therapeutic agent 
warrants further investigation. The TC50 (toxic concentration resulting in 50% cell death) 
against mouse fibroblasts was 3 µM, which is similar to the MICs against Candida species 
[66]. Minimum inhibitory concentrations (MICs) of occidiofungin against Candida 
species are submicromolar to micromolar, which is similar in activity to echinocandins 
and amphotericin B [66, 72, 73]. The target for occidiofungin is presumably present in 
most eukaryotic cells, given that the activity of occidiofungin against mouse fibroblasts 
and Candida species is only a few folds different. 
 
Before testing the efficacy of occidiofungin in an animal model or in humans, it is 
necessary to determine its toxicological profile. Substantial toxicity at doses expected to 
be required for antifungal efficacy would preclude further development of this compound 
as a therapeutic agent. Interestingly, a mouse toxicity study showed that doses higher than 
those commonly used to treat fungal infections did not result in mortality [74]. 
Furthermore, a dose administered intraperitoneally as high as 20 mg/kg resulted in no 
negative gross or microscopic findings in the liver or kidneys. Hematology and serum 
biochemistry tests also revealed that occidiofungin does not significantly alter organ 
function [74]. One possibility for the lack of observed organ specific toxicity in the 
previous mouse study is that occidiofungin did not absorb well into the circulatory system 
and that the lack of absorption was the reason for the lack of organ specific toxicity 
observed. 
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Considering that at the time of this work the target for the observed activity of 
occidiofungin was still unknown (actin) and that in vitro toxicity was seen in both fungal 
and mouse fibroblasts, the aim of this study was to evaluate the toxicity of occidiofungin 
in mice following intravenous administration along with its cytotoxicity against human 
cell lines. We found that cancer cell lines are hypersensitive to occidiofungin and that 
intravenous administration is well tolerated in the mouse model. Overall, our studies 
support the need for additional studies to evaluate occidiofungin's chemotherapeutic 
potential. 
 
Methods 
Mice.  Female BALB/c mice at age of 6 – 8 weeks old were used. Female mice were used 
instead of male mice, given that male mice generally exhibit more aggressive behavior. 
These mice were purchased from Harlan and allowed to acclimate at least 2 weeks after 
arrival. They were housed on a 12 hour light-dark cycle in a temperature and humidity 
controlled animal facility that is accredited by the American Association for Accreditation 
of Laboratory Animal Care. Animal care and use were in accord with NIH Guidelines and 
Texas A&M University regulations. Protocols used for the mice models were done in 
accordance to the methods reported by Luster et al [75]. 
 
Single Dose Toxicity Study [75]. Occidiofungin was produced as previously described 
and aliquoted and lyophilized into 100 µg quantities in 1.8 mL centrifuge tubes. Solubility 
of occidiofungin in aqueous buffers is relatively low. Mice (5 mice per group) were given 
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occidiofungin dissolved in 1.5% hydroxy propyl-beta-cylcodextrin suspended in 
phosphate buffered saline (PBS). Hydroxy propyl-beta-cyclodextrin has been used 
extensively in pre-clinical drug testing with little or no indication of meaningful effects 
[76].  Spectrometric inspection at O.D.600 following addition of vehicle to the purified 
dried drug had negligible absorbance difference to vehicle without drug, suggesting that 
the drug went into solution.  For the experiments, occidiofungin was administered by 
intravenous (i.v.) injection into the tail vein at a single dose at 5 mg/kg of body weight. 
The excipient control in each experiment matched the vehicle. Body weight and clinical 
signs (movement, posture, skin lesions, appearance of fur indicating normal grooming, 
and behaviors) were recorded following administration at one, four, eight, sixteen, and 
twenty-four hours. Necropsies were performed at 24 hours following administration of 
occidiofungin. 
Measurement of Toxicological Parameters [75]. Blood and tissue samples from animals 
dosed at 5 mg/kg of body weight with occidiofungin in 1.5% hydroxy propyl-beta-
cylcodextrin suspended in PBS were taken 24 hours following excipient or drug 
administration. Mice were anesthetized with isofluorane. Blood was then taken from the 
retroorbital plexus or heart puncture for serum biochemistry assays (alkaline phosphatase, 
alanine aminotransferase, aspartate aminotransferase, albumin, and blood urea nitrogen) 
and hematology (white blood cell count and white blood cell differentiation). Body weight 
was measured immediately before treatment and 24 hours later before the mice were fully 
anesthetized and fixed in 10% neutral buffered formalin. Histological examination was 
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performed on a portion of each organ by using routine paraffin embedding technique and 
staining with hematoxylin and eosin (H & E) [77]. All the sections were examined under 
light microscopy for pathological changes by a co-author of this paper, who is a board 
certified veterinary pathologist (J. C.). 
 
In Vitro Toxicity Screening 
Cancer cell lines, OVCAR8 (Center for Cancer Research (OVAR.8; Sample ID 25)), 
SW1088 (ATCC-HTB-12), and Toledo (ATCC CRL-2631), and normal human neonatal 
dermal fibroblasts (ATCC-PCS-201-010) cell line were passaged and prepped as 
previously described [78-80]. OVCAR8, SW1088, and Toledo2631 are an ovarian, brain, 
and B-cell lymphoma cancer cell lines, respectively. Cell counts per plate were calculated 
to be approximately 50,000 cells/mL. A 10X stock solution of occidiofungin was prepared 
at 65 µM concentration in 10% dimethyl sulfoxide (DMSO). Two-fold serial dilutions on 
a 96 well plate were set up in triplicate with starting concentration of 6.5 µM and a final 
concentration of 3 nM. Bortezomib was used as a comparator for toxicity against human 
fibroblast and was serially diluted two-fold starting at a concentration of 5 µM and ending 
at 2.5 nM. Bortezomib is used clinically against myeloma and lymphoma cancers in 
patients' refractory against other chemotherapeutics [81, 82]. The plates were then 
incubated at 37oC in 5% CO2 for 48 hours. After 48 hours, cell viability was monitored 
using CellTiter-Blue (Promega) cell viability assay by measuring the fluorescence 
emission of a redox activated dye (579EX/584EM) using a POLARstar Omega microplate 
reader (BMG Labtech). 
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Statistical Analysis 
Body weight, body weight change, organ weight, serum chemistry and hematology data 
were analyzed by T-test or two way ANOVA followed by Bonferroni post-test using 
Prism GraphPad software (San Diego, CA). All the analyses were two-sided, with p <0.05 
considered statistically significant. 
 
Results 
Anatomic and Clinical Pathology.  Results shown in Table 2 indicate the change in body 
weight following a single 5 mg/kg i.v. dose after 24 hours. Excipient treated mice body 
weight ranged between an 8% to 13% body weight gain after treatment and had a 9.6% 
average increase in body weight. Occidiofungin treated mice weight ranged between a 0% 
to a 21% body weight loss after treatment and had an average weight loss of 6.2%.  
A consistent behavioral response was observed at 1 hour and to a lesser extent at 4 hours 
post i.v. administration, in which the mice were more lethargic than excipient treated mice 
and had ruffled fur. They were responsive to touch, but would move slower than excipient 
treated mice. Treatment was not associated with more typical rodent behaviors associated 
with severe pain (e.g., writhing, vocalization, or lack of spontaneous locomotion). No 
other behavioral signs were observed.  Mice behavior appeared to be normal by 8, 16, and 
24 hour post injection. 
 
Generally, no macroscopic findings were observed by histological examination. No 
observable differences were present in the microscopic cell morphology or macroscopic 
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tissue morphology of esophagus, stomach, small intestine, colon, liver, pancreas, spleen, 
kidneys, lungs, heart and brain (Figure 7).  Albumin and blood urea nitrogen (BUN) tests 
were similar for occidiofungin treated and excipient treated mice (Table 2). These blood 
tests are indicative of normal kidney and to some extent liver function. In addition, alkaline 
phosphatase (ALP) tests were similar between drug and excipient treated mice (Table 1). 
These results indicate normal liver and bone cell function. Normally aspartate amino 
transferase (AST) and alanine aminotransferase (ALT) tests are performed in combination 
with ALP to assess liver function. Elevated levels of AST and ALT do suggest heart or 
liver damage, but do not necessarily indicate severe organ damage. Generally a ratio of 
AST to ALT less than one is indicative of liver damage. The ratio in all treated mice was 
greater than one, suggesting that the liver is not damaged. AST values ranged from 177 to 
1528 (U/l) with a mean value of 765 (U/l) and the ALT values ranged from 144 to 1273 
(U/l) with a mean value of 521 (U/l) (Table 2). Given the variability in AST and ALT 
levels in treated mice, only the ALT levels were statistically significant. 
White blood cell (WBC) counts were not statistically different between treated and 
untreated mice. This suggests that occidiofungin i.v. administration at 5 mg/kg had no 
cytotoxicological effect on blood cells or bone marrow. The absence of elevated levels 
further suggests normal spleen function. The percentage of neutrophils was statistically 
different in drug and excipient treated mice, while the percentages of lymphocytes were 
not statistically different (Table 2). The data does suggest an increase in the ratio of 
neutrophils to lymphocytes, which is indicative of an innate immune response to the drug. 
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However, additional mice and dosing regimens will need to be done to determine if this is 
a genuine response. Lastly, there was no statistical difference in platelet counts between 
drug and excipient treated mice, suggesting that occidiofungin does not affect platelet 
production by the bone marrow or destroy circulating platelets.    
In summary, there was no clear evidence for organ specific histological effects of 
occidiofungin. There were no apparent undesirable effects observed in the serum clinical 
chemistry and hematology parameters that would preclude additional animal testing of the 
compound. 
Cytotoxic Activity of Occidiofungin on Human Cell Lines. Bortezomib is a proteosome 
inhibitor that has been accepted by the medical community as a potent anticancer drug. It 
is a potent inhibitor of multiple myeloma and pancreatic tumor growth [81, 82]. The 
proteasome is a multi-catalytic, multi-subunit protease complex that is responsible for the 
ubiquitin-dependent turnover of cellular proteins [82-84]. Interference with the normal 
function of the proteosome by bortezomib affects cellular pathways that can interfere with 
transcription, release of cytokines, interfere with DNA repair machinery, and the 
activation of signalling kinase pathways that alters a cohort of cellular responses  [83-86]. 
These activities are exacerbated in multiple cancers. A typical LD50 value for bortezomib 
is between 20 and 50 nM, while its toxicity is in normal cells with lower metobolism is 
typically in the micromolar range [83, 87]. The activity of bortezomib was compared to 
the activity of occidiofungin against human fibroblasts. The activity of occidiofungin was 
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approximately eight-fold higher than that of bortezomib against the human fibroblast cell 
line used in this study  (Figure 8). 
 
These results suggest that the biological target of occidiofungin or the cellular effect due 
to the interaction with the target is augmented by the cellular physiology of the human 
cancer cell lines.  
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CHAPTER III 
SYNERGISTIC IMPLICATIONS OF A LANTIBIOTIC, MUTACIN 1140 AND AN 
AMINOGLYCOSIDE, KANAMYCIN IN COMBINATION AGAINST 
STAPHYLOCOCCUS AUREUS 
Overview 
Streptococcus mutans JH1140 is a strain of bacteria which produces a lantibiotic 
named mutacin 1140. Mutacin 1140 has been shown to be effective at inhibiting 
Gram-positive bacteria associated with Staphylococcus aureus and Streptococcus 
pneumoniae infections. Mutacin 1140 is a ribosomally synthesized peptide antibiotic 
that undergoes extensive posttranslational modifications (PTM). Microdilution plate 
assays show that when combined, mutacin 1140 and kanamycin, an aminoglycoside, 
displays synergistic behavior against S. aureus. The proposed mechanism of action for 
this synergistic behavior is different than kanamycin’s (30S ribosome action) individual 
mechanism of action, pointing to a cooperative membrane perturbation combined with 
cell wall inhibition. Confocal microscopy of propidium iodide stained cells treated 
with a combination of mutacin 1140 and kanamycin alluded to the possibility that 
combined, the effect of bacterial cell death is faster than individually against both 
Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). 
Additional studies, determining cell viability at 30 minutes by counting the colony 
forming units further showed that the combination of the antibiotics is more effective 
at inhibiting a clinically relevant bacterium Staphylococcus aureus. 
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Introduction  
Mutacin 1140 [38] was first isolated from Streptococcus mutans JH1140.This peptide  
shows the characteristic lanthionine structures found in this class of antibiotics called 
lantibiotics [88]. The presence of a lanthionine rings is common to all lantibiotics with 
nisin being the most studied representative lantibiotic.  The mechanism of action of 
mutacin 1140 is to sequester lipid II, preventing proper cell wall synthesis leading to a 
growth inhibitory effect on select Gram-positive bacteria.  In other lantibiotics, as in 
the case of nisin, the lipid II-lantibiotic complex form a pore structure in the cell wall; 
however mutacin 1140 does not exhibit these pore forming properties in 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) vesicles or against a tested strain of 
Streptococcus rattus [40]. Previous work [29] with bacteria mimetic vesicles 
containing 50 mM quenched carboxyfluorescein that were treated with submicromolar 
concentrations of mutacin 1140 (Figures 9 & 10) caused vesicles to lyse and release 
the carboxyfluorescein. The detection of the carboxyfluorescein release points to an 
alternative membrane disruptive activity of mutacin 1140. Additional studies showed 
that increasing the amount of the negatively charged lipid DOPG or the creation of a 
negatively charged membrane potential caused an increase in release of 
carboxyfluorescein. Up until the year 2000, research in the field implicated membrane 
perturbation as the mechanism of action for mutacin 1140 and other type AI 
lantibiotics and was later documented that lipid II sequestration was the primary basis 
for its mechanism of action. 
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Kanamycin is an aminoglycoside bactericidal antibiotic isolated from the bacterium 
Streptomyces kanamyceticus [89]. Aminoglycosides show very little effectiveness 
against fungi, anaerobic bacteria, and viruses. Aminoglycosides are effective primarily 
in infections involving aerobic, Gram-negative bacteria. In addition, some mycobacteria, 
including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. 
Kanamycin was discovered in 1957 by researchers in the National Institute of Health of 
Tokyo, Japan. It was isolated from a soil sample [90] and extracted with a cation 
exchange resin. It’s most used form is as kanamycin sulfate. It targets the 30S subunit of 
the ribosome, causing mistranslation of and indirectly inhibiting the process of protein 
synthesis translocation [91, 92]. This leads to a buildup of mistranslated proteins unable 
to perform their cellular function and the death of currently dividing cells [91]. 
Kanamycin is currently used as a second line treatment for hospital acquired infections, 
such as sepsis and urinary tract infections as well as its main use against tuberculosis 
[93] and is currently placed on the World Health Organization's List of Essential 
Medicines. Its classification on the list states that it is a backup second-line drug for the 
treatment of multidrug-resistant tuberculosis (MDR-TB).  
 
S. aureus is a Gram-positive bacteria normally found on the epidermis where moisture is 
present, as well as in the respiratory tract. Skin infections, food poisoning, and 
Abscesses are commonly caused by S. aureus. Staphylococcus was first identified by  
surgeon Sir Alexander Ogston in pus from a surgical abscess in 1880 [94]. While not 
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always pathogenic, pathogenic strains of S. aureus produce toxins which target cell 
surface receptors and cause apoptosis, and is linked or has been identified as a cause of 
several illnesses, including endocarditis, sepsis, meningitis, and pneumonia [95]. S. 
aureus exhibits resistance in multiple ways dependent on the antibiotic challenge it 
faces. For penicillin, S. aureus uses penicillinase, an enzyme which cleaves the β-lactam 
ring, causing penicillin to be ineffective. Glycopeptide resistance occurs by altering the 
peptidoglycan to which vancomycin will not be able to bind. Aminoglycoside resistance 
in S. aureus normally exhibits one of three generally accepted ways: mutations to the 
ribosome itself, modifying enzymes for aminoglycosides, and active pumping of the 
drug out of the bacteria by efflux.  
 
In this study, we evaluated the use of the lantibiotic mutacin 1140 in combination with 
a select panel of antibiotics. Synergy was confirmed between mutacin 1140 and the 
aminoglycoside kanamycin through microdilution studies, dose dependent kill curves, 
and colony forming unit (CFU) counts. Furthermore, propidium iodide (PI) staining 
and confocal microscopy shows that disruption of the bacterial membrane is faster in 
dose combination of mutacin 1140 and kanamycin than individually against both 
Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). 
In addition, several substitutions were made to determine if the synergistic behavior was 
class specific or only observed with single class of compounds. Tetracycline was 
substituted for kanamycin in combination with mutacin 1140 and nisin was substituted 
for mutacin 1140 in combination with kanamycin; both substitutions resulted in the loss 
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of the synergistic effects. However, there were improvements in inhibition with these 
antibiotic combinations, suggesting that the synergistic behavior observed between 
mutacin 1140 and kanamycin may have more to do with the class of antibiotics and not 
just these individual antibiotics. 
 
Methods 
Chemicals. Mutacin 1140 was produced and purified as previously described [26]. 
Other reagents were purchased from VWR and were of ACS grade purity unless 
stated otherwise. 
 
Media and Drug Preparation. THyex-M17 media (500 mL) containing 400 mL water, 
15 grams of Todd Hewitt media powder (BD), and 1.5 grams yeast extract (BD) was 
volume adjusted to 500 mL with dH20, sterilized at 121 °C for 35 minutes, and 
allowed to cool to room temperature. THyex agar plates were made in a similar 
method (7.5 grams agarose (BD) added) and poured while still warm under sterile 
conditions. These plates were then stored at 4 °C until use. As a precaution, the plates 
were preincubated before streaking to ensure no contamination was present. 
Antibiotics were not added to the agar. Antibiotic stocks (as well as all other drugs 
tested) were measured in 100 mg/mL concentration aliquots in water and diluted 
accordingly to the concentrations needed for each respective assay. New solutions 
were made for each day’s experiments and stored at -20 °C. 
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S. aureus Growth Parameters. Staphylococcus aureus was streaked on a solid agar 
THyex plate and allowed to grow overnight in an incubator set to 37 °C. A 5 mL THyex 
liquid culture was started using a single colony from a the overnight plate, and spun on a 
wheel at 37 °C until its optical density (OD) reached (OD 0.11-0.13) to meet the CLSI 
threshold of McFarland Standard of 0.5. The culture was then diluted 1:300 and then 
dosed with the drugs. Final S. aureus cell counts per well for starting concentration were 
at minimum 5x105 cells. All OD readings were taken by a Bio-Rad SmartSpec plus 
spectrophotometer. 
 
Microdilution Assay. Microdilution plate based assays were performed following a 
modified CLSI protocol. Bioassays were done using a 96-well plate with a final volume 
of 200 µL per well. Each assay was performed in triplicate wells. The 96-well plates were 
shaken at 170 RPM and allowed to grow at 37 °C; they were read at multiple time points 
by a spectrometer (Bio-Rad Xmark) in order to generate growth curves, as well as 
directly observed visually to see if the well showed growth or a change in opacity. Any 
growth present in the well that was visually distinguished was classified as ineffective 
antibiotic treatment. MICs were determined to be the highest concentration of antibiotic 
that inhibited the growth of the bacteria. As a follow up, plates were also stained with cell 
titer blue (promega G808A) which is a homogeneous, fluorometric method for visually 
confirming inhibition or growth of bacteria in multiwell plates. It uses the indicator dye 
resazurin to determine the metabolic capability of bacterial cells—an indicator of overall 
cell viability [96]. Active cells retain the ability to convert resazurin into resorufin, which 
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appears as a pink color and is highly fluorescent. Wells which stain blue and stay blue are 
not metabolically active and are probably dead.  
 
Checkerboard Assay. The combination effect of mutacin 1140 and kanamycin was 
determined by checkerboard assay [97] (Figure 11) and evaluated algebraically based on 
the fractional inhibitor concentration indices (FICs) . A total of 200 µL THyex media 
was distributed into each well of the 96-well plates. The first antibiotic (mutacin 1140) 
of the combination was serially diluted along the X-axis and upwards, while the second 
drug (kanamycin) was diluted along the Y-axis and to the right, where it shared a well 
with the respective vertical concentration of mutacin 1140. Each well was inoculated 
with 5x10
5 
cells Staphylococcus aureus grown as previously described, and the plates 
were incubated at 37°C for 24 hours under aerobic conditions.  One well with no 
antibiotic was used as a positive growth control on each plate. Plates were read for visual 
turbidity, and results were recorded after 24 h of incubation at 37°C in an enclosed 
shaker at 170 RPM (Thermo Scientific MaxQ 4000). 
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Kill Curves and CFU Counts. Staphylococcus aureus was grown as previously 
described in 10mL volumes, and then incubated with varying doses (4X, 2X, 1X, and 
0.5X MIC) of the aminoglycoside kanamycin, and the lantibiotic mutacin 1140. The 
volumes were then shaken together at 170 revolutions per minute (RPM) in combination 
over 24 hours at 37 °C in a Falcon™ 50 mL conical tube. During that 24 hours they were 
then tested using the CFU count method;100 µL of cell suspension from serially diluted 
cultures were plated on THyex agar and allowed to grow overnight at 37 °C. Several 
time points (0,2,4,8,12,20 hrs.) leading up to the final 24 hour time point were tested for 
colony forming units (CFUs). Colonies were then counted, both by hand independently 
by more than one lab member and assessed using OpenCFU software [98], allowing a 
reproducible extrapolation of the bacterial cell count at each time point in the presence, 
absence, and combination of the drugs. Plates with lawns or more than 300 colonies or 
less than 30 colonies were excluded and a dilution plate within this colony range was 
counted (Figure 12). 
 
Staining and Microscopy. A culture of Staphylococcus aureus was grown to a 
concentration high enough to yield a visible pellet when spun down. This was 
accomplished by inoculating 20 mL with one colony overnight, letting it grow up, and 
then taking 1 μL of that starter culture into a 10 mL experiment culture the following 
morning and monitoring its growth until it reaches an OD of 0.3. One mL aliquots were 
taken from the 10 mL experiment culture and placed in separate Eppendorf tubes and 
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spun down at 6500 RPM (3968 rcf) for 1 minute 30 seconds. 20 μL propidium iodide 
(ThermoFisher P3566)   was diluted into 2 mL of Annexin-V-FLUOS incubation buffer 
and then added in 200 μL quantities to each sample. The pellets were then resuspended 
with the 200 μL propidium iodide totaling 10 µg/mL final concentrations in each 
Eppendorf.   The tubes were then treated with doses of kanamycin and mutacin 1140 
both individually and together. Propidium iodide stain (PI) is a widely used red-
fluorescent nuclear and chromosome counterstain. Since propidium iodide is not 
permeant to live cells, it is also commonly used to detect dead cells in a population. 
Visual confirmation of red staining on microscopy indicates that the bacterial cell 
membrane has been compromised to the extent that the stain was allowed access to the 
nucleic acids. PI binds to DNA by inserting between the DNA bases without sequence 
preference. In aqueous solution, the dye has excitation/emission measurements of 
493/636 nm. Once the dye is bound, its fluorescence is enhanced 20- to 30-fold, the 
fluorescence excitation maximum is shifted ~30–40 nm to and the fluorescence emission 
maximum is shifted ~15 nm, resulting in an excitation maximum at 535 nm and 
fluorescence emission maximum at 617 nm [99].  
 
After 1 minute, 5 minutes, and 10 minutes elapsed for each respective sample, these PI-
incubated tubes were centrifuged at 6500 RPM on an Eppendorf 5424 microcentrifuge, 
decanted and then washed with 200 µL phosphate buffered saline (PBS) adjusted to 7.2 
PH. They were then immediately fixed with a 3.7% formaldehyde solution (EMD 
FX0410-5). A 30 μL volume of the fixed cells was pipetted from each sample onto a 
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separate glass slide with the P100 pipette tip snipped to avoid cell shearing, covered 
with a glass coverslip, and confocal microscopy images were then taken on an Olympus 
IX81 microscope. Figure 11 shows positive (1% Triton at 2 minutes exposure) and 
negative (no drug added) controls. Several images with multiple fields of view were 
taken, both in the presence and absence of the overlaid fluorescence filter. Cell counts 
were assessed using Olympus Micro FV10-ASW viewer software. Counts consisted of 
cells which glowed red under filter as well as the overall total number of cells in a field 
of view. By this method we were able to quantitate a percentage of cells in each view 
which featured compromised membranes compared to the total count of cells present.  
 
Results 
Lantibiotics have not yet been developed successfully as a clinical treatment option for 
bacterial infections. This is in part due to the difficulty in their production and in part to 
their short half-life in blood.  Furthermore, lantibiotics have a limited spectrum of 
activity in that they are only effective at treating Gram-positive bacterial infections. 
Whether lantibiotics will ever find their place in a clinical setting is unknown, and they 
may continue to be an academic exercise. The current approach for the clinical 
development of lantibiotics may be wrong and their place in the clinic may be in their 
use in combination with other approved antimicrobial drugs. Table 3 shows the 
beginning of our work of determining individual MICs against two strains of S. aureus 
and our activity indicator strain M. luteus. The short list of antibiotics target many of the 
clinically important targets, i.e. cell wall synthesis, membrane perturbation, and 
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translation. Table 2 results were determined with microdilution assays consisting of 3+ 
rows of serially diluted compounds individually plated against different bacteria strains. 
Microdilution assay results consistently showed rows of wells of both mutacin 1140 and 
kanamycin at MIC values individually able to clear the S. aureus bacteria from the well. 
Staining with cell titer blue confirmed that those wells with MIC concentrations had 
inhibited growth (they stayed blue). Microdilution assays also were used to assess the 
other antibiotics tested and form the basis for the individual MIC data shown in Table 3. 
 
Once we determined that the clinically relevant S. aureus was sensitive to the selected 
antibiotics, we further characterized their use in combination with mutacin 1140. The 
Gram-negative membrane disruptor (polymyxin B) is generally not effective against 
Gram-positive bacteria due to the thickness of their cell wall. We did test whether the 
combination of polymyxin B in combination with mutacin 1140 against the Gram 
negative bacteria Erwinia amylovora and Escherichia coli was more effective in a 
checkerboard assay, but there was no benefit to the addition of mutacin 1140 in these 
assays (data not shown). However, synergistic activity was observed between the 
aminoglycoside kanamycin and mutacin 1140 in the checkerboard assay (Figure 11). 
Individually, mutacin 1140 and kanamycin had low micromolar MICs of 6.25 and 3.25 
µg/mL, respectively. In the checkerboard assay, the effective MIC of each dropped by 
at least 4-fold when used in combination. Both mutacin 1140 and kanamycin MIC 
decreased to 0.78 µg/mL, an 8-fold decrease for mutacin 1140 and a 4-fold decrease for 
kanamycin (Figure 11). Thus, the checkerboard assay results showed synergy between 
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mutacin 1140 and kanamycin. This effect lasted past the 24 hour mark for assessing the 
plates after shaking and was reproducible with different stocks of mutacin 1140 and 
kanamycin (data not shown).  
 
The fractional inhibitory concentration (FIC) index (εFIC) was calculated as follows: 
εFIC= FIC A + FIC B 
Where FIC A is the MIC of the combination/MIC of drug A alone, and FIC B is the 
MIC of the combination/MIC of drug B alone. The threshold for synergy is met when 
the εFIC is <0.5, indifferent when the εFIC is >0.5 to <2, and antagonistic when the 
εFIC is >2 (Figure 11). FIC calculations for mutacin 1140 and kanamycin gave a value 
of .3748, well below the 0.5 synergy threshold. Mathematically each compound must 
have at least a four-fold reduction in MIC to reach the synergistic threshold (Figure 11). 
 
Additional studies were done to determine whether the observed synergy was 
compound specific or whether the observation could be observed between antibiotics 
from the same class of compounds (Table 4). Instead of mutacin 1140, we substituted 
nisin, another lantibiotic with a similar MOA targeting lipid II. The εFIC for the 
combination of nisin and kanamycin was 0.70. It did not meet the cutoff score for 
synergy, but there was a two-fold decrease and a four-fold decrease in the MIC for nisin 
and kanamycin when used in combination. There was no improvement in the activity of 
nisin when used in combination with another aminoglycoside gentamycin.  Of interest 
was a 32-fold reduction in activity of mutacin 1140 when used in combination with 
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gentamycin, but this didn’t meet the criteria for synergy given that there was only a 
twofold reduction in the activity of gentamycin. Mutacin 1140 was tested in 
combination with another aminoglycoside, streptomycin and other ribosomal inhibitors 
spectinomycin and tetracycline, but there was no change in the respective antibiotic 
inhibitory values.  Of note is the observed antagonistic behavior between vancomycin 
and mutacin 1140 (Table 4). A possible reason for this observed behavior is that 
mutacin 1140 and vancomycin share the same target in lipid II, albeit focusing on 
distinct binding sites. Perhaps the binding mechanisms of these two compounds restrict 
access to the other in competition for lipid II 
 
To further elaborate on our observed synergy we performed CFU kill curves with 
mutacin 1140 and kanamycin and determined that the result was reproducible in this 
assay as well. CFU count results (Figure 12) corroborated the observed microdilution 
assays. The combination of kanamycin and mutacin 1140 at 0.5 MIC concentration 
killed S. aureus faster and prevented substantial regrowth at the 24 hour time point. Sub 
MIC concentrations of mutacin 1140 and kanamycin repeatedly kept the test culture 
visibly clear for 24 hours, while simultaneously yielding no visible colony forming 
units on the corresponding time point agar plates (outside of time zero). In comparison, 
the no drug control as well as the sub MIC individual volumes plated a lawn of 
colonies. The media only control consistently did not show any colony forming units, 
demonstrating that no contamination was present. CFU’s also were visibly compared to 
model examples of S. aureus morphology and were confirmed by Gram-staining and 
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light microscopy (Olympus) during the preliminary portions of the experiment to be the 
expected Gram-positive bacterium.  
 
Improvement in the activity of mutacin 1140 were only observed when used in 
combination with the aminoglycosides kanamycin and gentamycin and was not observed 
with other translational inhibitors. It is possible that the synergy is due to the alternative 
mechanism of action of aminoglycosides, in which they disrupt membrane integrity. 
This is presumed to be attributed to the mistranslation of products into the cell 
membrane by the ribosomes associated with the inner leaflet of the membrane. The 
perturbation of the membrane combined with the cell wall synthesis inhibition by 
mutacin 1140 or the combined perturbation of the membrane by mutacin 1140 and 
kanamycin is attributed to the observed synergy.  In order to investigate a mechanism of 
action for why we were seeing synergy between mutacin 1140 and kanamycin, we set up 
a bacteria stain treatment using propidium iodide, a red binder of nucleic acids and 
membrane integrity indicator. Microscopy results (Figure 13, controls Figure 14) 
showed that chloramphenicol (15 µg/mL) is able to inhibit the bactericidal activity of 
kanamycin (0.5 x MIC). There was a reduction in membrane permeabilization when 
chloramphenicol was combined with mutacin 1140 and combined with the 0.5 MIC 
combination of mutacin 1140 and kanamycin. However, this data was not statistically 
significant.   Therefore, we returned to a CFU assay to observe the effect. Figure 15 
shows a time lapse comparison between 30 minutes incubation time of the combined and 
individual dosages of drugs and 24 hours incubation time.  In this study, a two-log 
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increase in colony forming units is observed when chloramphenicol is added to the 0.5 
MIC combination of mutacin 1140 and kanamycin. This data does show a protective 
function of chloramphenicol in this assay. From these results, it does support that the 
observed synergy is due to the alternate mechanism of action of the aminoglycosides, in 
that their membrane perturbation in combination with the lipid II binding of mutacin 
1140 is the likely cause for the observed synergy. This behavior was also conserved 
against the methicillin-resistant version of S. aureus. Future work that is needed is to 
determine whether the lantibiotic cell wall inhibition in combination with kanamycin 
membrane perturbation is the cause for the observed synergy or whether it is the 
combined membrane disruptive activity causing the synergy. This could be determined 
by a combination assay featuring vancomycin and kanamycin as well as amoxicillin and 
kanamycin. 
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CHAPTER IV  
DISCUSSION AND CONCLUSIONS 
 
Discussion 
Peptide therapeutics has been a strong source of clinically useful compounds and 
antibiotics. The previously described data for both mutacin 1140 and occidiofungin 
support the idea that peptide therapeutics and natural products have the potential for 
great clinical value.  In mutacin 1140, we have a lantibiotic with little resistance which 
targets a rarely modifiable, essential cell wall biosynthesis component lipid II. In 
combination with a 4-fold reduced MIC kanamycin mutacin 1140 delivers an 8-fold 
reduction in MIC, while also killing the bacteria at a faster rate than individually (cell 
destruction in 1 minute). Because mutacin 1140 resistant mutants have not been 
identified, the chemistry and structure of 1140 may prove valuable as a template for 
further development of synthetic antibiotics. Performing rational drug design or reverse 
target search using lipid II could yield a treasure trove of candidate compounds which by 
the nature of their target would be slow to acquire resistance. Decades of widespread 
clinical use of aminoglycosides has strongly reduced their clinical efficacy through the 
selection of resistant bacteria [100-102]. Having a candidate like mutacin 1140 would 
allow the resurrection of compounds relegated to second tier status due to resistance or 
cytotoxic effects and buy time for the antibiotic pipeline to yield new candidate drugs. 
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The antifungal activity of occidiofungin against a wide array of fungi has been tested. 
The antifungal activity was observed at micromolar to sub micromolar concentrations.  
In occidiofungin we have a known antifungal which has a target (actin) which is also a 
common target for cancer treatment. Work with occidiofungin and the cancer cell lines 
described in chapter II formed the basis of a United States patent for Occidiofungin 
formulations and uses thereof (PCT/US2015/049972). Initial acute mouse toxicity study 
was conducted following subcutaneous and intraperitoneal (i.p.) administration [74]. In 
this study, we describe a formulation that solubilizes occidiofungin at a concentration 
that enabled us to evaluate occidiofungin's toxicity following an intravenous route of 
administration. Furthermore, we evaluated occidiofungin's toxicity against human 
fibroblast and cancer cells lines. Interestingly, occidiofungin was found to be a potent 
inhibitor of these cancer cell lines, while there was no significant toxicity observed in 
mice following a single i.v. dose at 5 mg/kg. This concentration is about seventy-times 
higher than the concentration that was observed to kill the cancer cells in the in vitro 
toxicity assay. Our current study supports future work aimed at evaluating 
occidiofungin's potential for treating cancer.  
 
The in vitro toxicity in a rat hepatoma (H4IIE) cell line was observed at 5 μM, with a 
predicted TC50 value of 3 μM [74]. In this study, the in vitro toxicity against a human 
fibroblast cell line was observed at approximately 1 μM, with a predicted TC50 value 
around 0.5 μM. One key difference between these in vitro assays is the duration of drug 
exposure. The exposure time in this study was 48 hours, which is the typical exposure 
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time for evaluating cancer cell lines [87], while the exposure time against the mouse 
hepatoma cell line in our initial in vitro toxicity assay was only 24 hours [74]. Future 
studies aimed at evaluated cell viability over a period of time will enable a more complete 
understanding of the dynamics of cell death in these assays.  
   
In our previous mouse toxicity studies, it was clear that higher doses induced more body 
weight loss, and this change was dose-responsive [74]. However, body weight loss was 
not permanent and the mice would regain body weight when dosing ended. Lethargy and 
ruffled fur were observed in the single i.p. dose experiments on the first and second day 
after treatment [74]. The loss in body weight in conjunction with decreased thymus weight 
and the observed increase in neutrophil percentages suggests that occidiofungin causes a 
non-specific stress response. Activation of the hypothalamic-pituitary-adrenal axis by a 
non-specific stress response may increase circulating glucocorticoids that can cause 
apoptosis in developing thymocytes [103]. A loss in body weight was also observed 
following a 5 mg/kg i.v. administration of occidiofungin. In addition, mild lethargy and 
some ruffled fur were observed following the i.v. administration of occidiofungin. 
However, these behavioral changes were not as serious as what was observed following 
i.p. administration [74]. The mice were responsive and behaved normally by eight hours. 
There was also an increase in the percentage of neutrophils as observed in the previous 
study following the i.p. administration of occidiofungin. Future studies aimed at 
establishing the appropriate dosing regimen along with the administration of Ringers 
solution will need to be evaluated to determine whether the observed stress response can 
 44 
 
be alleviated. No other abnormal behavioral signs were observed. Histological 
examination of treated mice did not exhibit any signs of organ specific toxicity in our prior 
study following i.p. and subcutaneous administration [74] and  the mice did not exhibit 
any signs of organ specific toxicity in the current study following i.v. administration. Even 
at a relatively high dosage of 5 mg/kg, the lack of organ specific toxicity suggests that this 
compound may have minimal toxic effects and that the observed weight loss may be 
mitigated in future efficacy studies. 
 
Viability, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), 
reactive oxygen species (ROS) detection, membrane and cell wall stability, and membrane 
mimetic assays were used in a previous study to characterize the effect of occidiofungin 
on yeast cells [64]. Confocal and electron microscopy experiments were used to visualize 
morphological changes within treated cells. TUNEL and ROS detection assays revealed 
an increase in fluorescence with increasing concentrations of the antifungal. Yeast cells 
appeared to shrink in size and showed the presence of ‘dancing bodies’ at low drug 
concentrations (1μg/ml). Given that occidiofungin's base molecular weight is 1200 Da, 
this concentration is around 833 nM. A screen carried out on Saccharomyces cerevisiae 
gene deletion mutants in the apoptotic and autophagy pathways identified the apoptotic 
gene, Δyca1. Deletion of the yca1 gene provides a 2-fold increase in resistance. All of the 
autophagy mutants screened had no difference in sensitivity compared to the wild-type 
control [64]. Results from previous experiments demonstrate that yeast cells were dying 
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by an apoptotic mechanism of action. Additional studies are needed to determine whether 
the human cell lines die by apoptosis following exposure to occidiofungin.  
 
The Mutacin 1140 work done by our lab, in part presented here, represents a valuable 
opportunity at unlocking a class of novel peptides (lantibiotics) for use in alternative 
methods. Lantibiotics are both potent and have a broad spectrum of activity which would 
be invaluable in the clinic. Also, resurrecting other clinical compounds abandoned due to 
hepatotoxicity, resistance, and availability factors is within reach when combined in 
synergistic interactions, such as 1140 and kanamycin. Mutacin 1140 is bactericidal against 
S. aureus and has shown itself to be a synergistic partner against both wild type and 
resistant forms of S. aureus. Mutacin 1140, unlike vancomycin, interacts with the N-
acetylmuramic sugar (NAM), pyrophosphate, and the first isoprene and the development 
of resistance due to target modification is unlikely. 
 
Microscopy data suggests that mutacin 1140 killed at a faster rate than vancomycin or 
kanamycin, and killed more cells over the same period of time compared with any other 
tested drug individually. CFU count data illustrates that even at sub-MIC concentrations, 
when combined with kanamycin, mutacin 1140 inhibits S. aureus growth over a 24 hour 
period. We have data showing that there was no synergy observed between mutacin 110 
and other non-kanamycin translational inhibitors, as well as a loss of synergy (though still 
observed activity) when another cell wall inhibitor (nisin) was substituted for mutacin 
1140. If the mechanism of action for the observed synergy does not follow the known 
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MOAs for either compound individually, then perhaps the answer lies in these compounds 
acting in an alternate mechanism of action. To further study this, we performed a follow 
up experiment to attempt to assess the action and activity of kanamycin in our cells. Before 
exposing the cell pellet to kanamycin or mutacin 1140, we preincubated our propidium 
iodide staining sample pellets with chloramphenicol, an antibiotic which inhibits protein 
synthesis. It prevents protein chain elongation by inhibiting the peptidyl 
transferase activity of the bacterial ribosome. Theoretically, we would expect to see an 
impact on the activity of kanamycin in the presence of chloramphenicol. Our results show 
that the presence of chloramphenicol causes a marked decrease in kanamycin performance 
against S. aureus (Figure 13). Chloramphenicol also caused a 2 log difference in killing 
between mutacin 1140, kanamycin, and chloramphenicol in combination versus mutacin 
1140 and kanamycin in combination (Figure 15). Our most recent studies revealed a 
synergistic interaction between vancomycin (a cell wall synthesis inhibitor) and 
kanamycin (Figure 16). This data in addition to the synergy staining data and the 
checkerboard data points to our hypothesis that the membrane perturbation of kanamycin 
and perturbation of cell wall inhibitory activity of mutacin 1140 is working together 
simultaneously to cause rapid cell death.  
  
In summary, occidiofungin is a natural product produced by the soil bacterium 
Burkholderia contaminans MS14. It was discovered by its ability to inhibit the fungal 
pathogen of brown patch lawn disease [67]. A soil sample taken from a tuft of green grass 
surrounded by dead grass has led to the discovery of its potent antifungal activity. In this 
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study, we have found that occidiofungin also has a potent anticancer activity. Much of the 
recent focus on drug discovery has been spent on high throughput combinatorial chemistry 
approaches, which have not yielded the expected number of lead compounds for new 
chemotherapeutic testing [104]. Nearly half of all natural products used in the clinic have 
a microbial origin [104]. Our study, along with several other studies [104], demonstrates 
that there is still an enormous opportunity to identify novel natural products that can be 
further evaluated for their clinical efficacy in treating microbial infections or cancers. 
Additional studies in natural product discovery along with combinatorial chemistry can 
further expand the chances of identifying a compound that can save the lives of those in 
need. As research focuses oscillate, we need to be cautious of neglecting the potential of 
the microbial cell in drug discovery.  
 
Follow up experiments and future work for both mutacin 1140 and occidiofungin center 
on moving into an in vivo model. Can mutacin 1140 and kanamycin work in synergy 
against an active murine infection? What are the thresholds of dosages to optimize 
treatment in combination in vivo? It would be interesting to follow up with studies against 
kanamycin resistant strains. It would also be of interest whether inactive analogs of 
kanamycin have any improvement in mutacin 1140 activity. Perhaps setting up a mouse 
model with an indicator cancer strain like non-small cell lung cancer (NSCLC) and small 
cell lung cancer (SCLC) would be the first step in testing occidiofungin as a cancer 
therapeutic. Lung cancer is easily quantified in growth and morphology pre and post drug 
dose. 
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Overall, mutacin 1140 and occidiofungin are potent candidate compounds that feature 
alternative MOAs which were previously unreported. Mutacin 1140 possesses the ability 
to act in synergy with the aminoglycoside kanamycin, while occidiofungin has an 
alternative treatment characteristic in that it inhibits cancer cell lines. Both of these MOA’s 
have great value clinically, and should be leveraged and utilized to the utmost in drug 
development. While natural products research is not receiving the funding it once did from 
the largest pharmaceutical companies, candidates such as 1140 and occidiofungin form a 
powerful counterargument as to the efficacy, need, and versatility of this class of 
compounds for future drug studies in the never-ending push for novel antimicrobials. 
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APPENDIX A 
 FIGURES 
Figure 1 Mutacin 1140 and Nisin A structure. (Reprinted from [29]) 
 Lanthionine rings A and B comprise the lipid II binding domain, while the flexible 
hinge and terminal rings are believed to be important for lateral assembly of membrane 
complexes. Differences in peptide length are believed to be attributed to ability to form a 
membrane pore complex. 
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Figure 2 Mutacin 1140 synthesis.   
2A: Ribosomally synthesized peptide lanA. 2B: lanB action (dehydratase actor) 2C: 
lanC action (helps facilitate thioether connections and causes cyclization), 2D: lanD 
(decarboxylation action) and 2E: lanT, a transporter which allows the movement of the 
peptide followed by the action of lanP, a protease to cleave the leader sequence. 
A 
B 
C 
D 
E 
 64 
 
 
 
 
Figure 3 Structure of lipid II. (Reprinted from [40]) 
The triangle represents the site for the nitrobenzoxadiazole (NBD) labeling for 
microscopy studies. Mutacin 1140 interacts with the first isoprene, NAM, and 
pyrophasphate via the lanthionine rings A and B.  
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Figure 4 Covalent structure of occidiofungin.  
Amino acid positions: Asn/β-hydroxy Asn1, Novel Amino Acid (NAA2), Ser3, β-
hydroxy Tyr/chloro β-hydroxy Tyr4, 2,4-diaminobutyric acid (DABA)5, Gly6, Asn7, 
and Ser8. R1 and R2 represent natural variations in the covalent structure. R1 is either a 
proton or hydroxyl group and R2 is either a proton or chlorine. 
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Figure 5 In vitro interaction of occidiofungin with F- and G-actin. (Reprinted with 
permission from [62]) 
Affinity pulldown of actin using alkyne-OF: Lane 1-Protein MW ladder, Lane 2-100 ng 
pure F-actin, Lane 3-100 ng pure G-actin, Lane 4-Empty, Lane 5-F-actin treated with 
alkyne-OF, Lane 6-F-actin treated with native occidiofungin, Lane 7-F-actin treated with 
DMSO, Lane 8-G-actin treated with alkyne-OF, Lane 9-G-actin treated with native 
occidiofungin, Lane 10-G-actin treated with DMSO. 
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Figure 6 In vivo visualization of occidiofungin. (Reprinted with permission from [62]) 
Time course analysis (A-C) and competition with native occidiofungin (D-F) in a) 
Schizosaccharomyces pombe and b) Saccharomyces cerevisiae. Arrows indicate specific 
localization patterns observed in each cell at 10, 30, and 60 minutes.  
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Figure 7 Occidiofungin mouse histology slides. 
Representative magnifications of histological slides of mice treated with a 5 mg/kg i.v. 
dose. (A) Esophagus (200X magnification), (B) Stomach  (200X magnification), (C) 
Small Intestine  (200X magnification), (D) Colon  (200X magnification), (E) Liver  
(200X magnification), (F) Pancreas  (200X magnification), (G) Spleen  (200X 
magnification), (H) Kidney  (200X magnification), (I) Lung  (200X magnification), (J) 
Heart  (200X magnification), (K) Brain  (100X magnification), and (L) Brain (200X 
magnification). Histological examination was performed on a portion of each organ by 
using routine paraffin embedding technique and H & E staining. There were no 
histological abnormalities in the organ tissues of the treated mice in this experiment.  
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Figure 8 In vitro toxicity screen of occidiofungin. 
The TC50 values for occidiofungin against the OVCAR8 (green line and triangles), 
SW1088 (blue line and circles), and Toledo2631 (orange lines and open squares) cancer 
cell lines were 61 nM, 68 nM, and 70 nM, respectively. The TC50 value was 533 nM for 
occidiofungin, while it was 4,091 nM for bortezomib. These values are approximately 
eight-fold higher than that of the normal human primary dermal fibroblasts cell line tested. 
Furthermore, the activity against the cancer cell lines was ten to twenty-fold higher than 
what has been reported against Candida species. Results are mean of three independent 
experiments with one standard deviation. 
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Figure 9 Synthetic bilayer membranes. (Reprinted from [29]) 
Different combinations of DOPC (neutral headgroup) and DOPG (negative charged 
headgroup) lipids were used to make bilayer vesicles following Avanti Polar Lipids 
sonication protocol. Vesicles are made in buffered solution containing a self quenching 
concentration of carboxyfluorescein and separated on a sephadex column t remove free 
carboxyfluoroscein. 
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Figure 10 Measuring the fluorescence intensity of carboxyfluorescein release. 
(Reprinted from [29]) 
As mutacin 1140 was introduced to the vesicles, the effect of 1140 caused lysis 
behavior, releasing the trapped CF. Once free of the vesicle, the CF is detected as it is no 
longer quenched, signalling that the membrane has been ruptured. 
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Figure 11 Checkerboard microdilution. 
Result for mutacin 1140 combination with kanamycin against S. aureus. FIC calculation 
demonstrates synergy for the combined use of the antibiotics. 
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Figure 12 CFU counts for mutacin 1140 and kanamycin against S. aureus. 
The blue line represents the no drug control. The red line represents kanamycin 
individual dosing at .5x MIC. The green line represents .5X MIC dosing for mutacin 
1140. The purple line represents the combination dosing of both kanamycin and mutacin 
1140. 
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Figure 13 Propidium iodide staining data, S. aureus. 
Percent propidium iodide positive cells per field of view. Chloramphenicol (Cam) 
inhibits the activity of kanamycin (Kan). One percent Triton served as the positive 
control. The higher the percent of positive cells, the more cells were red (compromised) 
in the field of view. 
 
   
 
75 
Figure 14 Propidium iodide staining microscopy positive and negative controls. 
The top two panels are the negative controls, no drug present. The lower two panels are 
the 1% Triton positive controls for membrane permeabilization. The black panels are 
overlay filters which show the propidium iodide when active. 
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Figure 15 Viability of S. aureus following exposure to antibiotics. 
CFU counts were determined at 30 minutes (blue bar) and at 24 hours (red bar). 
77 
Figure 16 Checkerboard microdilution assay with vancomycin and kanamycin. 
Result for kanamycin in combination with vancomycin against S. aureus shows synergy 
with another lipid II binding antibiotic. FIC calculation demonstrates synergy for the 
combined use of the antibiotics, noted by yellow circle around example well. Individual 
MIC values for kanamycin is 3µg/mL and for vancomycin is 1.5µg/mL. FIC values are 
.25 for kanamycin (0.75µg/3.00µg) and .24 for vancomycin (0.37µg/0.75µg) for a total 
synergistic value of 0.49, meeting the threshold of <0.5 for synergy. 
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APPENDIX B  
 TABLES 
      Table 1 Spectrum of activity of occidiofungin  
 
       * -Azole resistant  # - Caspofungin resistant 
 
 
 
 
 
 
 
Strain Occidiofungin 
(g/ml) 
Voriconazole 
(g/ml) 
Fluconazole 
(g/ml) 
Other susceptible 
fungi: 
Rhizopus spp. 
Mucor spp. 
Fusarium spp.  
4-8 16 ->16 -  Alternaria 
alternata 
 Aspergillus 
fumigatus 
 Geotrichum 
candidum 
 Macrophomina 
phaseolina 
 Microsporum 
gypseum 
 Penicillium 
spp. 
 Pythium 
spinosum 
 Pythium 
ultimum 
 Rhizoctonia 
solani 
 Trichophyton 
mentagrophytes 
*Candida 
albicans 
*Candida 
krusei 
*Candida 
tropicalis 
2-4 1-2 - 
#Candida 
parapsilosis 
1-4 - 16->64 
 
#Cryoticiccus 
neoformans 
1-2 - 2-4 
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Table 2 Percent body weight change, serum chemistry and hematology following 
administration of drug and excipient control 
 
 Single IV Dose of 
Occidiofungin 
5 mg/kg            0 mg/kg 
*Weight Change % -6.2±9.9 +9.6±1.9 
   
Serum Biochemistry 
Albumin (g/ dl) 3.1±0.6 3.6±0.2 
BUN (mg/dl) 29.6±5 24.5±3.3 
ALP (U/l) 99±34 116±17 
AST (SGOT) U/l 765±692 165±81 
*ALT (SGPT) U/l 521±652 36±10 
   
Hematology   
WBC estimate 4750±1225 5830±1550 
*Neutrophils % 43±14 16±5 
Lymphocytes % 54±15 83±7 
Platelet estimate (xK/ul) 39±21 58±58 
Animals were sacrificed 24 hours following i.v. 
administration of occidiofungin. *Signifies 
statistically significant differences between treated 
and control group.  p <0.05 was considered 
statistically significant. 
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Table 3 Individual MICs 
 
    
Antibiotic MICs  µg/mL  µg/mL  µg/mL MOA Target 
Antibiotic Staphylococcus 
aureus 
MRSA Micrococcus 
luteus 
 
vancomycin 1 2.5 nd Lipid II 
polymyxin B >64 >64 >128 Membrane disruption 
spectinomycin 50 nd nd 30S Ribosome 
streptomycin 6.25 12.5 6.25 30S Ribosome 
gentamycin 5 nd nd 30S Ribosome 
kanamycin 3.25 3.25 nd 30S Ribosome 
mutacin 1140 6.25 6.25 0.125 Lipid II 
nisin 6.25 6.25 0.625 Lipid II (pore) 
tetracycline 12.5 12.5 nd 30S  
amoxicillin 3 >240 nd Peptidoglycan cross 
linking 
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Table 4 Combination MICs 
 µg/mL  µg/mL 
Antibiotic Staphylococcus aureus MRSA 
nisin/kanamycin 3.125/.8125 (.70) 6.25/2 (2) 
nisin/gentamycin 6.25/5(2) nd 
1140/tetracycline 6.25/12.5 (2) 3.125/12.5 (2) 
1140/spectinomycin 6.25/50 (2) nd 
1140/vancomycin 6.25/1.25 (2.25) 6.25/2.5 (2) 
1140/streptomycin 6.25/6.25 (2) 6.25/12.5 (2) 
1140/gentamycin .195/2.5 (.5312) nd 
1140/kanamycin .78/.8125 (.3748) .78/.25 (.3124) 
Green numbers mean the combination was synergistic, with 1140/gentamycin borderline 
synergistic but ultimately falling short of the threshold. Red numbers mean the 
combination was indifferent in activity. Yellow numbers means the interaction was 
antagonistic. These numbers are the FIC calculated values. Not detected (nd). 
